HIV treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review
R Patel, L Evitt, I Mariolis, S Di Giambenedetto… - Infectious Diseases and …, 2021 - Springer
The two-drug regimen dolutegravir plus lamivudine demonstrated durable efficacy for up to
3 years in phase III studies and a high barrier to resistance in treatment-naive and …
3 years in phase III studies and a high barrier to resistance in treatment-naive and …
Two‐drug vs. three‐drug combinations for HIV‐1: Do we have enough data to make the switch?
Three‐drug combination antiretroviral therapy (ART) became available in 1996, dramatically
improving the prognosis of people living with HIV. The clinical benefits of ART are due to the …
improving the prognosis of people living with HIV. The clinical benefits of ART are due to the …
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society–USA panel
Importance New data and therapeutic options warrant updated recommendations for the use
of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in adults. Objective To …
of antiretroviral drugs (ARVs) to treat or to prevent HIV infection in adults. Objective To …
Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment–naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 …
P Cahn, JS Madero, JR Arribas, A Antinori… - JAIDS Journal of …, 2020 - journals.lww.com
Background: The 2-drug regimen dolutegravir+ lamivudine was noninferior to dolutegravir+
tenofovir disoproxil fumarate/emtricitabine in achieving HIV-1 RNA< 50 copies/mL in …
tenofovir disoproxil fumarate/emtricitabine in achieving HIV-1 RNA< 50 copies/mL in …
Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 …
Background Primary analyses of the SWORD-1 and SWORD-2 trials at 48 weeks showed
that switching to a two-drug regimen of dolutegravir plus rilpivirine was non-inferior to …
that switching to a two-drug regimen of dolutegravir plus rilpivirine was non-inferior to …
Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial
BO Taiwo, VC Marconi, B Berzins… - Clinical Infectious …, 2018 - academic.oup.com
In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to
continuation of standard 3-drug maintenance antiretroviral therapy. There was no …
continuation of standard 3-drug maintenance antiretroviral therapy. There was no …
Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos (t) ides in virologically stable patients with …
JA Perez-Molina, R Rubio, A Rivero… - The Lancet Infectious …, 2015 - thelancet.com
Background Problems associated with lifelong antiretroviral therapy, such as need for strict
adherence, drug-related toxic effects, difficulties with treatment schedules, and cost, mean …
adherence, drug-related toxic effects, difficulties with treatment schedules, and cost, mean …
A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non …
R Landman, P de Truchis, L Assoumou, S Lambert… - The Lancet …, 2022 - thelancet.com
Background Intermittent (on 4 days per week) antiretroviral therapy (ART) for patients with
HIV-1 might be more convenient, better tolerated, and cheaper than continuous treatment …
HIV-1 might be more convenient, better tolerated, and cheaper than continuous treatment …
Dual therapy with darunavir and ritonavir plus lamivudine vs triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir …
F Pulido, E Ribera, M Lagarde… - Clinical Infectious …, 2017 - academic.oup.com
Background Our objective was to assess the therapeutic noninferiority of dual therapy with
darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus 2 …
darunavir/ritonavir and lamivudine compared to triple therapy with darunavir/ritonavir plus 2 …
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
F Maggiolo, R Gulminetti, L Pagnucco… - BMC infectious …, 2017 - Springer
Background Little is known about the applicability of dual treatments based on integrase
inhibitors. We explored the combination of lamivudine+ dolutegravir as an option when …
inhibitors. We explored the combination of lamivudine+ dolutegravir as an option when …